Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function.
Iain C MacdougallPiotr PonikowskiAustin G StackDavid C WheelerStefan D AnkerJaved ButlerGerasimos S FilippatosUdo-Michael GöhringBridget-Anne KirwanVasuki KumpesonMarco MetraGiuseppe RosanoFrank RuschitzkaPeter van der MeerSandra WächterEwa A JankowskaPublished in: Clinical journal of the American Society of Nephrology : CJASN (2023)
In a cohort of patients with acute heart failure, left ventricular ejection fraction <50%, and iron deficiency, the safety and efficacy of ferric carboxymaltose were consistent across a range of eGFR values.
Keyphrases
- iron deficiency
- acute heart failure
- ejection fraction
- heart failure
- aortic stenosis
- left ventricular
- small cell lung cancer
- cardiac resynchronization therapy
- epidermal growth factor receptor
- tyrosine kinase
- hypertrophic cardiomyopathy
- acute myocardial infarction
- left atrial
- mitral valve
- aortic valve
- coronary artery disease
- acute coronary syndrome